Kuur Therapeutics

Dan Lang, President of Cell Therapy

Oct. 13 | 5:45pm | AVROBIO Ballroom

Buffalo, NY

(NASDAQ: ATNX)

In-person Presentation

Kuur Therapeutics is developing CAR-NKT cells for treatment of cancer. Kuur has two ongoing Phase I trials and one preclinical program. Kuur was recently acquired by Athenex. Athenex is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The Kuur CAR-NKT cell technology will bolster the Athenex cell therapy pipeline, which already includes its High Affinity T cell receptor program.

www.athenex.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions